| 1. |
- Steer, S. J., et al.
(författare)
-
Single-particle Behavior at N=126: Isomeric Decays in Neutron-rich 204Pt
- 2008
-
Ingår i: Physical Review C (Nuclear Physics). - 0556-2813. ; 78:6
-
Tidskriftsartikel (refereegranskat)abstract
- The four proton-hole nucleus Pt-204 was populated in the fragmentation of an E/A = 1 GeV Pb-208 beam. The yrast structure of Pt-204 has been observed up to angular momentum I = 10h by detecting delayed gamma-ray transitions originating from metastable states. These long-lived excited states have been identified to have spin-parities of I-pi = (10(+)), (7(-)), and (5(-)) and half-lives of T-1/2 = 146(14) ns, 55(3) mu s, and 5.5(7) mu s, respectively. The structure of the magic N = 126 Pt-204 nucleus is discussed and understood in terms of the spherical shell model. The data suggest a revision of the two-body interaction for N = 126, Z < 82, which determines the evolution of nuclear structure toward the r-process waiting point nuclei.
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Russom, Aman, et al.
(författare)
-
Microfluidic leukocyte isolation for gene expression analysis in critically ill hospitalized patients
- 2008
-
Ingår i: Clinical Chemistry. - : Oxford University Press (OUP). - 0009-9147 .- 1530-8561. ; 54:5, s. 891-900
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Microarray technology is becoming a powerful tool for diagnostic, therapeutic, and prognostic applications. There is at present no consensus regarding the optimal technique to isolate nucleic acids from blood leukocyte populations for subsequent expression analyses. Current collection and processing techniques pose significant challenges in the clinical setting. Here, we report the clinical validation of a novel microfluidic leukocyte nucleic acid isolation technique for gene expression analysis from critically ill, hospitalized patients that can be readily used on small volumes of blood. METHODS: We processed whole blood from hospitalized patients after burn injury and severe blunt trauma according to the microfluidic and standard macroscale leukocyte isolation protocol. Side-by-side comparison of RNA quantity, quality, and genome-wide expression patterns was used to clinically validate the microfluidic technique. RESULTS: When the microfluidic protocol was used for processing, sufficient amounts of total RNA were obtained for genome-wide expression analysis from 0.5 mL whole blood. We found that the leukocyte expression patterns from samples processed using the 2 protocols were concordant, and there was less variability introduced as a result of harvesting method than there existed between individuals. CONCLUSIONS: The novel microfluidic approach achieves leukocyte isolation in <25 min, and the quality of nucleic acids and genome expression analysis is equivalent to or surpasses that obtained from macroscale approaches. Microfluidics can significantly improve the isolation of blood leukocytes for genomic analyses in the clinical setting. (c) 2008 American Association for Clinical Chemistry.
|
|
| 5. |
- Schlaepfer, T E, et al.
(författare)
-
Vagus nerve stimulation for depression: Efficacy and safety in a European study.
- 2008
-
Ingår i: Psychological Medicine. - 0033-2917 .- 1469-8978. ; 38:5, s. 651-661
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Vagus nerve stimulation (VNS) therapy is associated with a decrease in seizure frequency in partial-onset seizure patients. Initial trials suggest that it may be an effective treatment, with few side-effects, for intractable depression. Method: An open, uncontrolled European multi-centre study (D03) of VNS therapy was conducted, in addition to stable pharmacotherapy, in 74 patients with treatment-resistant depression (TRD). Treatment remained unchanged for the first 3 months; in the subsequent 9 months, medications and VNS dosing parameters were altered as indicated clinically. Results: The baseline 28-item Hamilton Depression Rating Scale (HAMD-28) score averaged 34. After 3 months of VNS, response rates (≥50% reduction in baseline scores) reached 37% and remission rates (HAMD-28 score <10) 17%. Response rates increased to 53% after 1 year of VNS, and remission rates reached 33%. Response was defined as sustained if no relapse occurred during the first year of VNS after response onset; 44% of patients met these criteria. Median time to response was 9 months. Most frequent side-effects were voice alteration (63% at 3 months of stimulation) and coughing (23%). Conclusions: VNS therapy was effective in reducing severity of depression; efficacy increased over time. Efficacy ratings were in the same range as those previously reported from a USA study using a similar protocol; at 12 months, reduction of symptom severity was significantly higher in the European sample. This might be explained by a small but significant difference in the baseline HAMD-28 score and the lower number of treatments in the current episode in the European study.
|
|
